clinical trial · NCT06304740
Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants
Inmagene LLC·phase1·terminated·n = 16
Healthy VolunteersIMG-007Placebo
brief summary
This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose.
started
Mar 6, 2024
primary completion
Aug 28, 2024
completion
Aug 28, 2024
last updated
Dec 12, 2024
official title
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of a Single Subcutaneous Dose of IMG-007 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol